Finally, Machine Learning Interprets Gene Regulation Clearly

In this age of "big data," artificial intelligence (AI) has become a valuable ally for scientists. Machine learning algorithms, for instance, are helping biologists make sense of the dizzying number of molecular signals that control how genes function. But as new algorithms are developed to analyze even more data, they also become more complex and more difficult to interpret. Quantitative biologists Justin B. Kinney and Ammar Tareen have a strategy to design advanced machine learning algorithms that are easier for biologists to understand.

The algorithms are a type of artificial neural network (ANN). Inspired by the way neurons connect and branch in the brain, ANNs are the computational foundations for advanced machine learning. And despite their name, ANNs are not exclusively used to study brains.

Biologists, like Tareen and Kinney, use ANNs to analyze data from an experimental method called a "massively parallel reporter assay" (MPRA) which investigates DNA. Using this data, quantitative biologists can make ANNs that predict which molecules control specific genes in a process called gene regulation.

Cells don't need all proteins all the time. Instead, they rely on complex molecular mechanisms to turn the genes that produce proteins on or off, as needed. When those regulations fail, disorder and disease usually follow.

"That mechanistic knowledge - understanding how something like gene regulation works - is very often the difference between being able to develop molecular therapies against diseases, and not being able to," Kinney said.

Unfortunately the way standard ANNs are shaped from MPRA data is very different from how scientists ask questions in the life sciences. This misalignment means that biologists find it difficult to interpret how gene regulation occurs.

Now, Kinney and Tareen developed a new approach that bridges the gap between computational tools and how biologists think. They created custom ANNs that mathematically reflect common concepts in biology concerning genes and the molecules that control them. In this way, the pair are essentially forcing their machine learning algorithms to process data in a way that a biologist can understand.

These efforts, Kinney explained, highlight how modern, industrial AI technologies can be optimized for use in the life sciences. Having verified this new strategy to make custom ANNs, Kinney's lab is applying it in investigating a wide variety of biological systems, including key gene circuits involved in human disease.

Ammar Tareen, Justin B Kinney.
Biophysical models of cis-regulation as interpretable neural networks.
bioRxiv 835942; doi: 10.1101/835942.

Most Popular Now

Researchers Capture First Images of Oxyg…

Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful. Hypoxia, or starvation of oxygen, in solid tumors is also thought to be...

VTT Makes New Investments in Digital Hea…

VTT is launching new research activities in the area of digital health as part of the growing wellbeing and health technology ecosystem in Kuopio. The new initiative aims to create...

A New Method of Artificial Intelligence …

Despite the immense progress in the field of AI in recent years, we are still very far from human intelligence. Indeed, if current AI techniques allow to train computer agents...

FDA Informs Health Care Providers, Facil…

Today, the U.S. Food and Drug Administration is issuing a safety communication informing health care providers, facilities and patients about cybersecurity vulnerabilities identified for certain GE Healthcare Clinical Information Central...

eHealthWeek 2020 Croatia - Trusted Infor…

15 - 17 April 2020, Rovinj, Croatia. In its capacity of hosting the upcoming Presidency of the Council of the European Union, the Croatian Ministry of Health is in preparations to...

Siemens Healthineers Presents Solutions …

CT scanners with intelligent user guidance, AI-based software assistants for MRI and a lab system that revolutionizes workflows: Siemens Healthineers is showcasing its products and solutions according to the motto...

NHS IT Chiefs Set the Stage for a Year o…

3 - 4 March 2019, London, United Kingdom. NHS technology leaders are to kick off the second-ever Digital Health Rewired Conference and Exhibition on 3 - 4 March at the Olympia...

PatchAi Startup has Arrived in the Marke…

PatchAi - a startup that offers, thanks to Artificial Intelligence and Machine Learning, an empathic virtual assistant to patients participating in clinical trials - announced that it has closed two...

Digital Health App Medicus AI Earns CE C…

Medicus AI, the Vienna-based health tech company, has received a ​Class I Medical Device CE Mark for its mobile application. The CE certification mark confirms that Medicus AI conforms to...

FDA Authorizes Marketing of First Cardia…

Today, the U.S. Food and Drug Administration authorized marketing of software to assist medical professionals in the acquisition of cardiac ultrasound, or echocardiography, images. The software, called Caption Guidance, is...

Human Body-on-Chip Platform Enables In V…

Drug development is an extremely arduous and costly process, and failure rates in clinical trials that test new drugs for their safety and efficacy in humans remain very high. According...

AI in Drug Discovery Conference 2020

16 - 17 March 2020, London, UK. SMi group presents the launch of the inaugural AI in Drug Discovery conference taking place in London. AI-empowered machine learning technologies hold the potential...